• Panobinostat Targets Epigenetic Vulnerabilities in MLL-ALL

  2026-04-30

  This study demonstrates that panobinostat, a histone deacetylase inhibitor, exerts potent in vivo anti-leukaemic effects in models of MLL-rearranged infant acute lymphoblastic leukaemia (ALL) by disrupting the RNF20/RNF40/WAC-H2B ubiquitination axis. These findings establish a mechanistic framework for targeting epigenetic maintenance pathways in aggressive ALL subtypes, informing future therapeutic strategies.

• Mitochondrial Calcium Signaling Controls Ferroptosis via GPX

  2026-04-29

  This study reveals that mitochondrial calcium uptake, mediated by the MCU channel, is essential for repressing ferroptosis through regulation of GPX4 acetylation and activity. The findings establish a mechanistic link between mitochondrial metabolism and ferroptotic cell death, with implications for targeting ferroptosis in cancer and organ injury models.

• IEM 1460: Applied Workflows for AMPA Receptor Blocker Resear

  2026-04-29

  IEM 1460 sets the gold standard for selective AMPA receptor inhibition in neuroscience workflows, offering reliability in excitotoxicity and neuroprotection assays. This article delivers protocol refinements, troubleshooting strategies, and evidence-based insights to help researchers achieve reproducible and high-impact results.

• PD 0332991 (Palbociclib) HCl: Precision Workflows for Tumor

  2026-04-28

  PD 0332991 (Palbociclib) HCl enables highly selective, reproducible G1 cell cycle arrest and robust antiproliferative assessment in translational cancer models. This guide details actionable, data-driven workflows, troubleshooting tactics, and the latest mechanistic advances—empowering researchers to drive deeper insights into CDK4/6 signaling and Rb pathway inhibition.

• Fluorescein TSA Fluorescence System Kit: Amplifying Low-Abun

  2026-04-28

  The Fluorescein TSA Fluorescence System Kit empowers researchers to detect and localize low-abundance proteins and nucleic acids in fixed tissues with unprecedented sensitivity. By leveraging tyramide signal amplification and optimized workflow steps, this kit delivers clear, reproducible results even in challenging applications such as immunohistochemistry and in situ hybridization.

• Septin4 Promotes Hypoxic Injury in Cardiomyocytes via HIF-1α

  2026-04-27

  This study uncovers a novel mechanism by which Septin4 exacerbates hypoxia-induced cardiomyocyte injury through promoting HIF-1α ubiquitination and degradation via the VHL pathway. These findings highlight the crucial interplay between apoptosis regulators and hypoxia signaling in myocardial ischemia, suggesting new avenues for targeted research and therapeutic modulation.

• Caspase-3 Fluorometric Assay Kit: Precision in Apoptosis Ass

  2026-04-27

  Unlock rapid, quantitative apoptosis insights using the Caspase-3 Fluorometric Assay Kit from APExBIO. This kit streamlines DEVD-dependent caspase activity detection, offering robust troubleshooting, workflow efficiency, and sensitive measurement critical for oncology and neurodegeneration research.

• ddhCTP in Antiviral Assays: Workflow, Application & Troubles

  2026-04-26

  Leverage ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) from APExBIO for robust, literature-validated inhibition of RNA virus replication in cellular models. This guide details setup, optimization, and troubleshooting to ensure high-fidelity antiviral assay data, with protocol parameters and insights from recent mechanistic studies.

• BRD4 Inhibitors Enhance Erastin-Induced Ferroptosis via ROS

  2026-04-25

  This study demonstrates that BRD4 inhibitors, including I-BET-762, amplify erastin-induced ferroptosis across diverse cell lines by increasing ROS accumulation and downregulating FSP1. These findings clarify the mechanistic interplay between epigenetic regulators and ferroptosis, with implications for combination cancer therapies.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-04-24

  The referenced study demonstrates that the fluoropyrimidine polymer CF10, when combined with 5-ethynyl-2′-deoxyuridine (EdU), produces synergistic cytotoxicity in colorectal cancer (CRC) cells via enhanced telomere attrition and mitotic catastrophe. This mechanism, distinct from classic thymidylate synthase inhibition, offers a new paradigm for targeting telomerase and telomere integrity in oncology research.

• Moxidectin-Polyenes Synergy: Boosting Antifungal Effect via

  2026-04-24

  This article reviews a 2024 study that demonstrates how moxidectin increases ergosterol biosynthesis in Candida albicans, enhancing the efficacy of polyene antifungals like nystatin in oral candidiasis models. The findings suggest a promising strategy to overcome antifungal resistance and improve clinical management of Candida infections.

• Expandable Nanocomposite Hemostat for Noncompressible Hemorr

  2026-04-23

  A novel nanocomposite-coated shape-memory foam hemostat demonstrates rapid expansion, significant reduction in clotting time, and excellent biocompatibility for treating noncompressible hemorrhage. This approach advances the field of internal hemostatic biomaterials, addressing limitations of conventional gauze and hydrogel-based interventions.

• Everolimus (RAD001) for Advanced mTOR Inhibition Workflows

  2026-04-23

  Everolimus (RAD001) stands out as a rigorously characterized, orally bioavailable mTOR inhibitor, enabling precise dissection of cancer cell proliferation and apoptosis mechanisms. This guide translates cutting-edge in vitro and in vivo research into actionable protocols, troubleshooting, and workflow enhancements for oncology and immunology labs.

• Paclitaxel (Taxol): Mechanistic Leverage for Translational O

  2026-04-22

  Explore how Paclitaxel (Taxol) reshapes cancer research via microtubule stabilization, cell cycle arrest, and anti-angiogenic action. This thought-leadership article from APExBIO bridges deep molecular mechanisms with translational strategy, integrating the latest literature and protocol guidance for researchers targeting chemoresistance and advancing next-generation oncology therapeutics.

• Primaquine Mitigates Retinal Ferroptosis via GSTA1 Activatio

  2026-04-22

  This study identifies primaquine as a novel ferroptosis inhibitor that protects retinal neurons from ischemia/reperfusion (I/R)-induced death by upregulating GSTA1 activity. The findings highlight a previously unexplored mechanism of neuroprotection, with implications for targeting ferroptosis in retinal pathology.

16185 records 1/1079 page Next 12345 下5页 Last page